Host immune response and inflammatory cytokine networks in the gut

The host immune response and inflammatory cytokine networks in the gut represent a complex physiological system responsible for maintaining mucosal homeostasis and defending against enteric pathogens (Neurath, 2014, Nature Reviews Immunology). This network involves a delicate balance between pro-inflammatory cytokines, such as Tumor Necrosis Factor (TNF), Interleukin-12 (IL-12), and Interleukin-23 (IL-23), and anti-inflammatory signals like Interleukin-10 (IL-10) (Friedrich et al., 2019, Nature Reviews Gastroenterology & Hepatology). In pathological states like Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis, this balance is disrupted, leading to chronic inflammation and tissue damage (Strober & Fuss, 2011, Gastroenterology). The immune response is mediated by various cell types, including T cells, B cells, macrophages, and dendritic cells, which communicate through these cytokine networks (Mowat & Agace, 2014, Nature Reviews Immunology). Therapeutic intervention focuses on modulating specific nodes within this network using monoclonal antibodies or small molecule inhibitors. For instance, anti-TNF agents and IL-12/23 antagonists are widely used to suppress the overactive immune response and induce clinical remission in patients with refractory gut inflammation (Raine et al., 2022, Journal of Crohn's and Colitis). Additionally, newer therapies target leukocyte trafficking or intracellular signaling pathways like the JAK-STAT pathway to restore intestinal harmony (Danese et al., 2019, Nature Reviews Gastroenterology & Hepatology).

Other names

Gut mucosal immune systemIntestinal cytokine networkGastrointestinal immune responseGut-associated lymphoid tissue (GALT) response

Therapeutic agents modulate this network by neutralizing pro-inflammatory cytokines (e.g., TNF-alpha, IL-12, IL-23), blocking cytokine receptors, inhibiting intracellular signaling pathways such as the JAK-STAT pathway, or preventing the trafficking of inflammatory cells to the gut mucosa via integrin antagonism.